Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Gobom

Showing results (121-130 of 139) with videos related to

Pageof 14
Sort By:
Clinical Chemistry and Laboratory Medicine|November 13, 2021
Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluidJohan Gobom, Lucilla Parnetti, Pedro Rosa-Neto, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 14, 2022
Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiologyAurore Delvenne, Johan Gobom, Betty Tijms, et al.
Medrxiv : the Preprint Server for Health Sciences|November 11, 2020
Cerebrospinal fluid total tau levels indicate aberrant neuronal plasticity in Alzheimer's diseasePieter Jelle Visser, Lianne M Reus, Johan Gobom, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 14, 2025
Cerebrospinal fluid proteomic associations of APOE genotypes reveal distinct protective and risk mechanisms for Alzheimer's diseaseEleonora M Vromen, Senne B Lageman, Johan Gobom, et al.
Molecular Neurodegeneration|January 7, 2024
Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer's disease pathologyJoseph Therriault, Marcel S Woo, Gemma Salvadó, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 6, 2024
CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's diseaseAurore Delvenne, Johan Gobom, Suzanne E Schindler, et al.
Biomarkers in Medicine|August 25, 2012
Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42Niklas Mattsson, Ingrid Zegers, Ulf Andreasson, et al.
Nature Communications|July 2, 2025
Proteomic analysis of Down syndrome cerebrospinal fluid compared to late-onset and autosomal dominant Alzheimer´s diseaseLaia Montoliu-Gaya, Shijia Bian, Eric B Dammer, et al.
Fluids and Barriers of the CNS|July 17, 2024
Involvement of the choroid plexus in Alzheimer's disease pathophysiology: findings from mouse and human proteomic studiesAurore Delvenne, Charysse Vandendriessche, Johan Gobom, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 6, 2020
First amyloid β1-42 certified reference material for re-calibrating commercial immunoassaysSébastien Boulo, Julia Kuhlmann, Ulf Andreasson, et al.
Pageof 14

Showing results (121-130 of 139) with videos related to

Sort By:
Pageof 14
Clinical Chemistry and Laboratory Medicine|November 13, 2021
Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluidJohan Gobom, Lucilla Parnetti, Pedro Rosa-Neto, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 14, 2022
Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiologyAurore Delvenne, Johan Gobom, Betty Tijms, et al.
Medrxiv : the Preprint Server for Health Sciences|November 11, 2020
Cerebrospinal fluid total tau levels indicate aberrant neuronal plasticity in Alzheimer's diseasePieter Jelle Visser, Lianne M Reus, Johan Gobom, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 14, 2025
Cerebrospinal fluid proteomic associations of APOE genotypes reveal distinct protective and risk mechanisms for Alzheimer's diseaseEleonora M Vromen, Senne B Lageman, Johan Gobom, et al.
Molecular Neurodegeneration|January 7, 2024
Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer's disease pathologyJoseph Therriault, Marcel S Woo, Gemma Salvadó, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 6, 2024
CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's diseaseAurore Delvenne, Johan Gobom, Suzanne E Schindler, et al.
Biomarkers in Medicine|August 25, 2012
Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42Niklas Mattsson, Ingrid Zegers, Ulf Andreasson, et al.
Nature Communications|July 2, 2025
Proteomic analysis of Down syndrome cerebrospinal fluid compared to late-onset and autosomal dominant Alzheimer´s diseaseLaia Montoliu-Gaya, Shijia Bian, Eric B Dammer, et al.
Fluids and Barriers of the CNS|July 17, 2024
Involvement of the choroid plexus in Alzheimer's disease pathophysiology: findings from mouse and human proteomic studiesAurore Delvenne, Charysse Vandendriessche, Johan Gobom, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 6, 2020
First amyloid β1-42 certified reference material for re-calibrating commercial immunoassaysSébastien Boulo, Julia Kuhlmann, Ulf Andreasson, et al.
Pageof 14